Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SCIEX : Builds on Cadence of Innovation in Biopharma With Biologics Explorer

09/01/2021 | 11:01am EDT

New application software enables protein characterization analysis for the ZenoTOF 7600 system

SCIEX, a global leader in life science analytical technologies and Danaher operating company, launches Biologics Explorer software, enabling customers to acquire insights from their high-resolution protein characterization data, and reach decisions quickly and confidently on the most important critical quality attributes for biopharmaceuticals. Biologics Explorer signifies the next step in innovation, building upon the ZenoTOF 7600 system, alongside Molecule Profiler.

To bring life-saving protein therapeutics to market safely and rapidly, it is critical to fully characterize candidate molecules at every stage of development. Biologics Explorer allows scientists to harness the full potential of the incredibly rich spectra produced from the Zeno trap and electron activated dissociation (EAD), from the ZenoTOF 7600 system, into highly informative and actionable results. These results are based upon a nodal algorithm structure that enables each processing and analysis step to be optimized so scientists can get the clear answers they need from their assays.

“The launch of the ZenoTOF 7600 system is the beginning of new possibilities for biopharmaceutical scientists and sets the pace for a cadence of innovation,” said Mani Krishnan, VP GM, CE & Biopharma at SCIEX. “While Molecule Profiler extended the ZenoTOF 7600 system’s capabilities into oligonucleotides, Biologics Explorer extends the reach once more, this time into protein therapeutics. Together, the ZenoTOF 7600 system with these new software applications will provide fresh and deeper insights for biologic manufacturers, allowing them to rapidly progress their therapies through the pipeline.”

The strategic software partnership between SCIEX and Genedata allows for this expansion of functionality. Biologics Explorer is built upon Genedata Expressionist®, industry-leading enterprise software platform for biopharmaceutical mass spectrometry.

“I am delighted to see the value delivered by our software platform as an out-of-the-box desktop solution addressing the specific needs of SCIEX customers. Partnerships like this help to deliver new capabilities to the wider biopharma community and enable the opportunity for an enterprise implementation with Genedata Expressionist where required,” said Othmar Pfannes, Ph.D., CEO of Genedata.

Currently available workflows include intact and subunit analysis, PTM determination and MAM, peptide mapping by EAD or CID and disulfide bond analysis.

To learn more about the Biologics Explorer and other software offerings, visit here.


SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have led the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher (NYSE: DHR) family of global science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com.

Let’s connect: Twitter, LinkedIn, Facebook, and Instagram.

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-13757-A.

© Business Wire 2021
10/22DANAHER : Baird Adjusts Danaher's Price Target to $340 from $305, Keeps Outperform Rating
10/22DANAHER : Wells Fargo Adjusts Danaher's Price Target to $340 from $320, Keeps Overweight R..
10/22DANAHER : Goldman Sachs Adjusts Danaher's Price Target to $345 from $335, Keeps Buy Rating
10/22DANAHER : Jefferies Adjusts Danaher's Price Target to $360 from $325, Keeps Buy Rating
10/22DANAHER : KeyBanc Adjusts Price Target on Danaher to $345 from $315, Keeps Overweight Rati..
10/22DANAHER : Barclays Adjusts Price Target on Danaher to $355 From $335, Maintains Overweight..
10/22DANAHER : RBC Lifts Price Target on Danaher to $334 From $332, Maintains Sector Perform
10/21GLOBAL MARKETS LIVE : Tesla, Unilever, Paypal, Elliott, Novartis...
10/21DANAHER : Reports Higher Third-Quarter Earnings, Beating Estimates; Raises 2021 Core Reven..
10/21DANAHER : Posts Higher Q3 Adjusted Earnings, Sales
More news
Analyst Recommendations on DANAHER CORPORATION
More recommendations
Financials (USD)
Sales 2021 29 000 M - -
Net income 2021 6 048 M - -
Net Debt 2021 19 545 M - -
P/E ratio 2021 38,4x
Yield 2021 0,28%
Capitalization 224 B 224 B -
EV / Sales 2021 8,40x
EV / Sales 2022 7,75x
Nbr of Employees 68 000
Free-Float 74,1%
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 20
Last Close Price 313,38 $
Average target price 339,17 $
Spread / Average Target 8,23%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose Carlos Gutiérrez Ramos Chief Science Officer & Senior Vice President
Brian W. Ellis Senior Vice President & General Counsel
Sector and Competitors